(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 28 February 2002 (28.02.2002)

PCT

(10) International Publication Number WO 02/016551 A3

(51) International Patent Classification⁷: C07H 21/04, 21/02, A61K 48/00, C12P 19/34

(21) International Application Number: PCT/US01/26101

(22) International Filing Date: 20 August 2001 (20.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/226,197 18 August 2000 (18.08.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US 60/226,197 (CON) Filed on 18 August 2000 (18.08.2000)

- (71) Applicant (for all designated States except US): UNIVER-SITY OF MASSACHUSETTS MEDICAL CENTER [US/US]; Suite 130, 365 Plantation Street, Worcester, MA 01605 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHOI, Yongwon [—/US]; 325 E. 84th, Apt. 5A, New York, NY 10028 (US). ODGREN, Paul, R. [US/US]; 181 Ball Hill Road, Princeton, MA 01541 (US). MARKS, Sandy, C., Jr. [US/US]; 226 West Main Street, Westboro, MA 01581 (US).

- (74) Agent: FASSE, J., Peter; Fish & Richardson, P.C., 225 Franklin Street, Boston, MA 02110 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report:

13 March 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: TRANCE REGULATION OF CHONDROCYTE DIFFERENTIATION

(57) Abstract: Disclosed are therapeutic methods of treating a mammal, e.g., a human patient, having a disease, disorder or condition characterized by abnormal (excessive or insufficient) cartilage growth or skeletal growth. The methods include inhibiting or supplementing activity of TRANCE or TRAF6 in chondrocytes in vivo or ex vivo. Also disclosed are methods of diagnosing a cartilage disorder. The method includes detecting an elevated or reduced level of TRANCE, RANK, or TRAF6 in chondrocytes. Also disclosed are methods of identifying a compound that increases or decreases proliferation of chondrocytes, or a compound that promotes differentiation, e.g., maturation, of chondrocytes.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/26101

A. CLASSIFICATION OF SUBJECT MATTER						
IPC(7) :C07H 21/04, 21/02; A61K 48/00; C12P 19/34 US CL :Please See Extra Sheet.						
According to International Patent Classification (IPC) or to both national classification and IPC						
	ocumentation searched (classification system followe	,				
U.S. : 435/6, 91.1, 325, 375; 536/23.1, 24.5, 24.3, 24.31, 24.33; 514/44						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic o	lata base consulted during the international search (name of data base and, where practicable	e, search terms used)			
STN, MEDLINE, CAPLUS, LIFESCI, EMBASSE, USPATFULL, BIOSIS						
C. DOCUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where ap	ppropriate, of the relevant passages	Relevant to claim No.			
Y	KINPARA ET AL. Osteoclast Diffe Osteosarcome Cell Line. Journal of Vol. 21, No. 4, pages 327-340.		1-33			
Y, P	PEARSE ET AL. Administration of the Trance-Antagonist TR-FC Limits Myeloma-Induced Bone Destruction. Blood. 16 November 2000, Vol. 96, No. 11, Part 1, page 549a.		1-33			
Y	NAKAGAWA ET AL. RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in Osteoclastogenesis. Biochemical and Biophysical Research Communications. 16 March 1998, Vol. 253, pages 395-400.		1-33			
X Further documents are listed in the continuation of Box C. See patent family annex.						
• Spe	ecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the appl				
	ument defining the general state of the art which is not considered be of particular relevance	the principle or theory underlying the				
	lier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider				
cite	nument which may throw doubts on priority claim(s) or which is do to establish the publication date of another citation or other	"Y" document of particular relevance; the	claimed invention cannot be			
"O" doc	cial reason (as specified) ument referring to an oral disclosure, use, exhibition or other	considered to involve an inventive step with one or more other such docum	when the document is combined			
"P" doc	obvious to a person skilled in the accument published prior to the international filing date but later "&" document member of the same pater and the priority date claimed		family			
		Date of mailing of the internation see	arch report			
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer D. Roberts for KAREN A. LACOURCIERE				
_	o. (703) 305-3230	Telephone No. (703) 308-1235				

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/26101

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Category	creation of document, with indication, where appropriate, of the relevant passages	relevant to claim ivo
Y	NAGAI ET AL. Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast Formation. Biochemical and Biophysical Research Communications. 16 March 2000, Vol. 269, pages 532-536.	1-33
Y	KOBAYASHI ET AL. Tumor Necrosis Factor A Stimulates Osteoclast Differentiation by a mechanism Independent of the ODF/RANKL-RANK Interaction. J. Exp. Med. 17 January 2000, Vol. 191, No. 2, pages 275-285.	1-33
Y	TAKAI ET AL. Transforming Growth Factor-B Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells. The Journal of Biological Chemistry. 16 October 1998, Vol. 273, No. 42, pages 27091-27096.	1-33
Y	WO 99/29865 A2 (THE ROCKEFELLER UNIVERSITY) 17 June 1999 (17.06.99), see entire document.	1-33
Y	WO 97/40192 A1 (TULARIK, INC.) 30 October 1997 (30.10.97), see entire document.	1-33
Y	WO 98/46751 A1 (AMGEN INC.) 22 October 1998 (22.10.98), see entire document.	1-33
1		14.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US01/26101

A. CLASSIFICATION OF SUBJECT MATTER: US CL :				
485/6, 91.1, 825, 375; 536/23.1, 24.5, 24.3, 24.31, 24.33; 514/44				